These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34636513)

  • 41. A status report on topical tazarotene in the management of acne vulgaris.
    Del Rosso JQ; Tanghetti E
    J Drugs Dermatol; 2013 Mar; 12(3):s53-8. PubMed ID: 23545935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
    Tanghetti EA; Bhatia N; Drew S; Jacobson A
    J Drugs Dermatol; 2021 Aug; 20(8):829-836. PubMed ID: 34397206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
    Thiboutot D; Arsonnaud S; Soto P
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
    Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
    J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-Pruritic Efficacy of Itch Relief Lotion and Cream in Patients With Atopic History: Comparison With Hydrocortisone Cream.
    Zirwas MJ; Barkovic S
    J Drugs Dermatol; 2017 Mar; 16(3):243-247. PubMed ID: 28301620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
    Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
    J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
    Shalita A
    Cutis; 2004 Oct; 74(4 Suppl):4-8. PubMed ID: 15543713
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
    Tan J; Draelos ZD; Gooderham MJ; Alexis AF; Graber E; Keri J; Woolery-Lloyd HC; Harper JC; Cook-Bolden FE; Konda A; Tanghetti EA
    J Clin Aesthet Dermatol; 2023 Sep; 16(9):42-45. PubMed ID: 37720201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
    Grove G; Zerweck C; Houser T; Andrasfay A; Gauthier B; Holland C; Piacquadio D
    J Drugs Dermatol; 2017 Feb; 16(2):140-144. PubMed ID: 28300856
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion.
    Del Rosso J; Han G; Armstrong A; Lewitt GM; Jacobson A
    J Drugs Dermatol; 2023 Feb; 22(2):132-138. PubMed ID: 36745378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Topical formulation and dermal delivery of active phenolic compounds in the Thai medicinal plant--Clerodendrum petasites S. Moore.
    Thitilertdecha P; Rowan MG; Guy RH
    Int J Pharm; 2015 Jan; 478(1):39-45. PubMed ID: 25445977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
    Draelos ZD; Tanghetti EA;
    Cutis; 2002 Feb; 69(2 Suppl):20-9. PubMed ID: 12095065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
    Han G; Armstrong AW; Desai SR; Guenin E
    J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin.
    Machtinger LA; Kaidbey K; Lim J; Loven KH; Rist TE; Wilson DC; Parizadeh DD; Sefton J; Holland JM; Walker PS
    Br J Dermatol; 2004 Dec; 151(6):1245-52. PubMed ID: 15606521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.